Swipe to the left

New Assay | Ranibizumab (Lucentis®) (mAb-based) ELISA

March 15, 2018

The drug Ranibizumab (trade name Lucentis®) is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment (Fab) designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons. The ImmunoGuide Ranibizumab ELISA (mAb-based) kit can be efficiently used for measuring free Ranibizumab levels in aqueous humour.

This ELISA is based on a Ranibizumab-specific monoclonal antibody (catcher Ab, ImmunoGuide clone 2A1). Diluted standards and samples are incubated in the microtiter plate coated with IG-2A1 mAb. After incubation, the wells are washed. A biotinylated anti-human kappa light chain monoclonal antibody (clone ImmunoGuide 7G8(Z) is added and binds to the kappa light chain part of Ranibizumab. Following incubation, wells are washed, and the horseradish peroxidase (HRP)-conjugated streptavidin is added and binds to the biotinylated 7G8(Z) mAb. Following incubation, wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. The colour developed is proportional to the amount of Ranibizumab in the sample or standard. Results of samples can be determined by using the standard curve. Preincubation of Ranibizumab with recombinant human VEGF inhibited the reaction.

Ranibizumab (Lucentis®) (mAb-based) ELISA

Catalog NumberTM09034
DesignEnzyme immunoassay (ELISA) technique.
Standards5 standards, dilute 1:10 prior to use.
ControlsNone provided.
Sample TypesAqueous humour
Sample Volume5 µL
Assay Desc.1 hour incubation (RT) + 30 min. (RT) + 30 min. (RT) + 15 min. (RT) = 2 hour, 15 min. total incubation time.
Standard Range0 / 10 - 300 ng/mL
Sensitivity0.33 ng/mL
Storage2 - 8 °C
Configuration96 Determinations, 12x8 removable strips.
FDA StatusFor research use only, not for use in diagnostic procedures.

View the package insert here.

Product Spotlight | Prorenin Receptor Protein ELISA

March 7, 2018

(Pro)renin receptor/(P)RR is a common receptor protein between renin and prorenin. It has an ability equivalent to renin to bind angiotensinogen and a catalytic activity for conversion from angiotensinogen to angiotensin I once it binds to the (P)RR. Additionally, its intracellular signal transmission promotes once the (P)RR is stimulated by binding with prorenin. From the fact, it is believed that (P)RR research is important for development of strategy for a new remedy which enable to suppress over activated tissue RAA (Renin-Angiotensin-Aldosterone) system. (P)RR is a 39 kDa, single transmembrane receptor protein and it is reported that it generates 29 kDa soluble form cleaved by furin. Thus the quantitative assay of soluble (P)RR in blood or urine samples is expected to contribute a new perception for clarification of disease mechanisms and development of new tools for diseases. This assay kit is enabled to measure the concentration of soluble (Pro)renin receptor in human, mouse and rat blood or urine samples.

Soluble (Pro)renin Receptor ELISA

Catalog Number27782
DesignSolid phase sandwich ELISA using 2 kinds of highly specific antibodies.
Standards8 standards, serially diluted from 1 prepared lyophilized standard.
ControlsNone provided.
Sample TypesHuman: serum, EDTA-plasma, urine.
Mouse and Rat: serum, EDTA-plasma.
Cell culture supernatant.
Sample Volume100 μL of properly diluted unknown / determination.
Assay Desc.Overnight incubation (4°C) + 1 hour (4°C) + 30 min. (RT) = Overnight + 1 hour, 30 min. total incubation time.
Standard Range0 / 125 - 8000 pg/mL
Sensitivity24 pg/mL
Storage2 - 8 °C
Configuration96 Determinations, 12x8 removable strips
FDA StatusFor research use only, not for use in diagnostic procedures.

Complement System MBL (Lectin) ELISA | An Overview

March 2, 2018


The complement system plays an essential role in chronic, autoimmune and infectious disease. There are three pathways of complement activation, namely the classical, the alternative and the MBL pathway.

Impaired complement activity causes humans to become susceptible to repetitive fulminant or severe infections and may contribute to development of autoimmune disease. Inappropriate activation of complement contributes to chronic inflammation and tissue injury.

Technical Information

The MBL Complement assay combines principles of the hemolytic assay for complement activation with the use of labeled antibodies specific for neoantigen produced as a result of complement activation. The amount of neoantigen generated is proportional to the functional activity of complement pathways.

In the Complement Screen MP kit the wells of the microtitre strips are coated with specific activators of the MBL pathway. Serum is diluted in diluent containing specific blocker to ensure that only the MBL pathway is activated. During the incubation of the subject's serum in the wells, complement is activated by the specific coating.

The wells are then washed and C5b-9 is detected with a specific alkaline phosphatase labelled antibody to the neoantigen expressed during MAC formation.

After a further washing step, detection of specific antibodies is obtained by incubation with alkaline phosphatase substrate solution. The amount of complement activation correlates with the colour intensity and is measured in terms of absorbance (optical density (OD))

Kit Components and Storage

- One frame with green break-apart wells (12x8) sealed in a foil pack with a desiccation sachet. The wells have been coated with mannan.

- 35 mL Diluent MP (Dil MP), labelled green.

- 13 mL conjugate containing alkaline phosphatase-labelled antibodies to C5b-9 (blue colour).

- 13 mL Substrate solution ready to use.

- 30 mL wash solution 30x concentrated.

- 0,2 mL negative control (NC) containing human serum. (to be diluted as for a subject's serum sample).

- 0,2 mL positive control (PC) containing freezed dried human serum, see “Reconstitution of positive control”, IFU

All reagents in the kit are ready for use except washing solution and controls. The reagents should be stored at 2-8° C except the positive control.

The positive control should be stored at -20° C.

View the package insert here.

IL-36γ and IL-37 Cytokine ELISAs

February 14, 2018

ELISA Kit for IL-36γ (Specific Marker for Psoriasis)

IL-36γ is a specific marker for Psoriasis. This assay is highly specific for human IL-36γ. Does not cross-react with human IL-36α and IL-36β.

Sensitivity: 3 pg/ml | Range: 3.9 to 250 pg/ml | Sample: Serum, Cell Culture Supernatant

IL-36α (IL-1F6), IL-36β (IL-1F8) and IL-36γ (IL-1F9) are members of the IL-1 cytokine family that bind to IL-36R (IL-1Rrp2) and IL-1RAcP, activating similar intracellular signals as IL-1 and are inhibited by IL-36Ra. The expression of IL-36 cytokines occurs mainly in the lung and skin and can be derived from diverse epithelial cell types including keratinocytes, bronchial epithelium as well as macrophages, monocytes and different T cell subsets. IL-36 family members induce the production of pro-inflammatory cytokines, including IL-12, IL-1β, IL-6, TNF-α and IL-23, thus promoting neutrophil influx, dendritic cell (DC) activation, polarization of T helper type 1 (Th1) and IL-17-producing T cells (αβ T cells and γδ T cells) and keratinocyte proliferation. Induction of IL-36γ in macrophages upon M. tuberculosis infection and its role in the release of antimicrobial peptides has been proposed. IL-36γ is also induced in the lung in various models of asthma and can be produced by bronchial epithelial cells in response to viral infection, smoke or inflammatory cytokines and plays an important role in asthmatic pulmonary inflammation. IL-36γ might be a potential biomarker of Inflammatory Bowel Disease and is highly expressed in inflamed skin from psoriasis subjects and in Allergic Contact Dermatitis. IL-36γ serum levels are enhanced and correlate to psoriasis severity and response to treatment with anti-TNF.

IL-36γ (human) ELISA Kit (IB99529)

ELISA Kit for IL-37 (A New Anti-inflammatory IL-1 Family Member)

IL-37 is a new anti-inflammatory cytokine. This assay detects natural and recombinant monomeric and dimeric human IL-37.

Sensitivity: 10 pg/ml | Range: 16 to 1000 pg/ml | Sample: Serum, Plasma

IL-37 (IL-1F7; IL-1H4) is an IL-1 family member that is expressed only in certain types of human organs and cells such as heart, thymus, testis, kidney, mononuclear cells (PBMCs) and dendritic cells. IL-37 is an inhibitor of innate immunity with anti-inflammatory properties. It binds to the interleukin-18 receptor (IL-18R) and its co-receptor SIGIRR. IL-37 is secreted as a full-length and as a processed form starting from amino acid Val46. It plays an important role as a link between innate and adaptive immunity and acts as an inhibitor of autoimmune diseases and tumor growth. IL-37 also inhibited Lipopolysaccharide (LPS)-induced immunological reaction and LPS-induced osteoclast formation and bone resorption. A recent study indicates that IL-37 protein forms a head-to-head homodimer and this structure limits its bioactivity. Variants with mutations converting the cytokine into a monomeric form are 13 fold more active than the dimeric IL-37.

IL-37 (human) ELISA Kit (IB99511)

View our wide selection of related Cytokine and Cell Signaling products

The Art of ImmunoGuide: Research Drug Monitoring Assays

February 7, 2018

Our Research Drug Monitoring ELISA Kits are highly sensitive and specific assay tests for determining the concentration of Adalimumab, Infliximab, Rituximab,Tocilizumab and many more in serum and plasma.

These Research Drug Monitoring ELISA Assay Kits can be used for university research, pharmaceutical research, or clinical research. Each kit comes with specialized instructions regarding the incubation time required, dynamic range, sample type, as well as kit reagent contents. The trade name for these products is ImmunoGuide. These are very useful ELISA test kits for the measurement of drugs (antibodies against TNF-alpha and others) and the antibody against these drugs (ATI and others). ImmunoGuide kits were developed by a senior immunology professor who is the member of our partner's scientific team. Development is underway of more products of this group in order to match with the ongoing development of new drugs.

Below we spotlight our Tocilizumab ELISA (mAb-based) Cat# IG-AB108

Double-monoclonal antibody enzyme immunoassay for the quantitative determination of free Tocilizumab in human serum and plasma.

  • The most specific kit in the market by the advantage of using monoclonal antibodies for coating the wells (capture-mab) and in the conjugate (tracer-mab) specific to Tocilizumab (Actemra) only.
  • Measures only the free form of Tocilizumab (not Tocilizumab molecules that are already bound to IL-6 Receptor or anti-Tocilizumab-antibodies).
  • Efficient monitoring of Tocilizumab serum level during therapy is essential for the subject's follow-up.
  • Eliminating the risk of potential high-dose related side effects and development of anti-Tocilizumab antibodies.
  • User friendly test protocol, ready to use reagents, short run time.
  • No reaction with any other proteins present in native human serum.
  • No reaction with the other therapeutic monoclonal antibodies.
  • The lowest detectable level that can be specifically distinguished from the zero standard is 10 ng/mL.

View our complete selection of Research Drug Monitoring ELISA assays:

Adalimumab (Humira®)



Adalimumab (Humira®) Control Set



Aflibercept (Eylea®, Zaltrap®)



Anti-Adalimumab (Humira®)



Anti-Adalimumab (Humira®) Confirmatory Reagent



Anti-Bevacizumab (Avastin®)



Anti-Cetuximab (Erbitux®)



Anti-Etanercept (Enbrel®)



Anti-Golimumab (Simponi®)



Anti-Infliximab (Remicade®) (ATI)



Anti-Infliximab (Remicade®) (Total)



Anti-Infliximab (Remicade®) Confirmatory Reagent



Anti-Nivolumab (Opdivo®)



Anti-Omalizumab (Xolair®)



Anti-Rituximab (Rituxan®)



Anti-Tocilizumab (Actemra®)



Anti-Trastuzumab (Herceptin®)



Anti-Vedolizumab (Entyvio®)



Bevacizumab (Avastin®)



Bevacizumab (Avastin®) (mAb-based)



Certolizumab pegol (Cimzia®) (mAb-based)



Cetuximab (Erbitux®) (mAb-based)



Etanercept (Enbrel®)



Etanercept (Enbrel®) (mAb-based)



Golimumab (Simponi®)



Golimumab (Simponi®) (mAb-based)



Infliximab (Remicade®)



Infliximab (Remicade®) (mAb-based)



Infliximab (Remicade®) Control Set



Nivolumab (Opdivo®) (mAb-based)



Omalizumab (Xolair®) (mAb-based)



Rituximab (Rituxan®) (mAb-based)



Tocilizumab (Actemra®) (mAb-based)



Trastuzumab (Herceptin®)



Trastuzumab (Herceptin®) (mAb-based)



Ustekinumab (Stelara®) (mAb-based)



Vedolizumab (Entyvio®) (mAb-based)